Arvinas Inc. competitors

Eric Poma, Ph.D. has served as Molecular Templates’ Chief Executive Officer and Chief Scientific Officer since the Company’s inception in 2009.From March 2005 until September 2008, Eric Poma was Vice President of Business Development of Innovive Pharmaceuticals (acquired by Cytrx Corporation), a biotechnology company. From 2001 to 2005, he served as the Associate Vice President of Business Development at ImClone Systems, Inc.(now Eli Lilly and Company) a biotechnology company focused on antibody therapeutics. As the founder and in his role as Chief Scientific Officer at MTEM, he led the invention of technology underlying MTEM’s platform technology and what constitutes the whole of MTEM’s current lead and preclinical pipeline candidates. Eric Poma received his Ph.D. in Microbiology and Immunology and B.A. in Biology and from the University of North Carolina at Chapel Hill and his M.B.A. from New York University.

Mr. George B. Kauffman is a Chairman Chief Executive Officer;Chief Investment Officier at RIGEL PHARMACEUTICALS INC and is based in United States.

Founder Aedio • Worked at @massachusetts-general-hospital-mgh, @brigham-women-s-hospital • Studied at @tufts-university

As a senior executive with 20+ years of sell- and buy- side business and corporate development experience, my career encompasses roles in therapeutics, biotech, genomics, medical devices, and pharmacy benefits. During my tenure at Pfizer, I completed more than 2 dozen acquisition, co-development, and licensing deals ranging from $300M to $7B. Later at Foundation Medicine, I led the $1B sale of their genomics testing to Roche, and earlier played a leadership role in Medco’s $29B sale to Express Scripts. I have worked extensively within R&D environments and launched 3 $1B+ therapeutic products in the hypertension and antibiotics categories. Additionally, I have been the CEO of early stage start-ups, building the funding, commercialization, and exit strategy for therapeutics companies in the CNS and autoimmune disease space.Currently, as CEO of Cognition Therapeutics, I am driving Series C fundraising effort. With multiple phase 2 clinical trials well under way for the Alzheimer’s research and more than a hundred million dollars in dedicated funding, I am repositioning the company to broaden the focus on our science and other CNS clinical conditions. I am pleased to lead a company dedicated to halting neurological disease processes and restoring and preserving the building blocks of brain health and function and look forward to sharing our progress here.

David Shanahan is a Chairman of the Board at G-CON Manufacturing, Managing Director at Endurance Capital, and Chairman Of The Board at Lab7 Systems and is based in Dallas, Texas. He has worked as President at Mary Crowley Cancer Research Center. David attended Texas A&M University between 1981 and 1985.

Robert Alexander has been involved in the formation and leadership of numerous biotechnology companies. Robert Alexander was CEO of ZS Pharma where he led the initial public offering and sale of ZS Pharma to AstraZeneca. Prior to ZS Pharma, Robert Alexander was a Director at Alta Partners, a venture capital firm, and was also Executive Chairman and interim CEO of SARcode Bioscience. During his time at Alta Partners, he led investments in SARcode Bioscience (acquired by Shire), Lumena Pharmaceuticals (acquired by Shire), ZS Pharma (acquired by AstraZeneca), and Allakos. Prior to Alta Partners, Robert was a Principal in MPM Capital’s BioEquities Fund. Robert Alexander joined MPM from Genentech, where he worked in the Business Development group. Robert Alexander is on the Board of Directors of Allena Pharmaceuticals. He holds a PhD from the University of North Carolina at Chapel Hill and a Bachelor Science in Zoology from Miami University of Ohio.